SkinBioTherapeutics (SBTX): Mark H Dixon and Diana Dixon towards control
This situation live
SBTX SkinBioTherapeutics
12 May 2026 · 26.971% (from 0%) · −41% since
Mark H Dixon and Diana Dixon: 26.971%
Mark H Dixon and Diana Dixon towards control
26.971% (from 0%)
HolderMark H Dixon and Diana Dixon
Stake0% → 26.971%
Crossed25%
As of 12 May 2026 ↗
Since Oct 2023: 117 situations of this kind – no bid within a year 92%, a bid followed 8%; median share price +3% six months after they opened
Every step · 1
- 12 May 2026 26.971% (from 0%) – Mark H Dixon and Diana Dixon: 26.971% ↗
What is happening
SkinBioTherapeutics: Mark H Dixon and Diana Dixon towards control – 26.971% (from 0%). ['26.971% (from 0%)']
- In short
- Mark H Dixon and Diana Dixon raised its stake in SkinBioTherapeutics from 0% to 26.971% on 12 May 2026, crossing 25%.
- Announced
- 12 May 2026 · 26.971%
From the company's own announcements. Not investment advice.
Briefing Pro
New to SkinBioTherapeutics? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the SBTX briefing →Also at SkinBioTherapeutics 2 open
New CEO / resetBoard and management changes – CEO and Chair made permanent; NED imminent
Legal & regulatoryFY25 accounts restatement and financial review – Restated results published; shares restored 8 June
Upgrade / downgrade cycleProfit warning – profit warning · fourth in 12 months · closed
SkinBioTherapeutics – company page →